Stanford Health Care’s menopause treatment information names progesterone. That is more specific than a generic reference to hormones, but less specific than a product label. It should not be expanded into a claim about every progestogen, every route or a particular micronized capsule.
Reviewed September 29, 2026, this assessment follows the active-ingredient question through Stanford’s public treatment description and separate regulatory references. It confirms relevant clinical care while leaving the exact formulation, manufacturer and dispensing arrangement unresolved. No personal prescription or clinical result is inferred from the terminology.
Read this article by section
Retain the hormone that the treatment page actually names
Stanford’s treatment information discusses progesterone within its hormone-therapy explanation. The word should be reported accurately rather than casually replaced with a broader category. The page nevertheless does not identify a particular micronized product or its manufacturer.
The UCLA assessment examines another service where educational terminology is clearer about a category than about a finished medicine. In Stanford’s case, identifying the hormone is a useful piece of the record, not the last piece. This review does not treat the public explanation as a prescription, a capsule’s ingredient list or confirmation that every clinician in the system uses the same formulation.
The umbrella term includes distinctions that matter
The FDA’s menopause-therapy explanation uses progestogen as a category that includes progesterone and progestin. Those terms should not be flattened into interchangeable product names. A statement about a category may be less specific than a statement about its individual members.
Our progesterone-versus-progestin guide follows that vocabulary. The distinction does not establish clinical superiority for the hormone Stanford names or determine which option an individual should receive. It means the active ingredient must remain identifiable when evidence is discussed. A review loses precision if it changes the substance in a sentence while leaving the original study, warning or claim attached to it.
A study description cannot be transferred by changing a noun
The exact Prometrium label discusses Women’s Health Initiative evidence involving conjugated estrogens with medroxyprogesterone acetate. Those are the studied ingredients named in that part of the label. This review does not relabel that study as a Stanford trial of an unspecified micronized progesterone product.
The point is evidence attribution, not a claim that a different hormone is free of risk. Nor does the study discussion establish Stanford’s chosen medicine. Product-specific warnings and clinical interpretation remain necessary. The label is a separate reference illustrating why the ingredients and formulation in evidence must be retained; it is not proof of the prescription, manufacturing source or treatment outcome associated with this provider. A differently named preparation would require its own record; matching the hormone word alone would not complete that comparison of the actual evidence.
Micronized and route remain additional unresolved properties
Stanford’s treatment page includes a broader menu of hormone-delivery forms. It does not map progesterone to every route listed or provide a complete micronized product record. The reader should not build a formulation by joining separate general statements.
The micronized meaning guide and route comparison address distinct properties. Neither authorizes changing a medicine’s route. For a provider comparison, Duke’s review examines a similarly broad delivery menu beside a progesterone reference. These pages make relevant treatment subjects visible while leaving product-specific evidence and actual supply unconfirmed.
A treatment explanation is not an individual decision rule
The Stanford overview describes menopause symptoms, assessment and care rather than a self-service product selector. A general explanation of a hormone’s role should be read within that professional context. This article does not calculate a personal need, choose a medicine or resolve the significance of someone’s surgical or medical history.
That boundary remains important even when the vocabulary is precise. Correctly identifying progesterone is not enough to decide whether it should be used. A clinician’s reasoning must concern the person and the particular proposal, not simply whether a term appears on a reputable website. No universal regimen, treatment duration or automatic exception is supplied by this review.
Consultation access and medicine supply are different findings
Stanford’s treatment information presents in-person and video appointment options. This is access information for care, not proof that all readers can obtain a remote prescription or that a particular progesterone product is dispensed through one channel. Conditions and availability require confirmation with the service.
The public records reviewed do not establish a complete price for a selected consultation and medicine. They also do not prove pharmacy stock, insurance payment or a shipped order. A service review can document appointment options without becoming a transaction report. The distinction prevents a broad access statement from being promoted into a national capsule offer that the source has not actually made.
Precision means preserving both what is named and what is missing
Stanford’s published treatment discussion supports the specific observation that progesterone is named within relevant menopause care. It does not support a complete micronized product identity. Both parts of that conclusion matter: the hormone should not be blurred, and the missing formulation should not be invented.
A later proposal could make the finished medicine and its intended use clear enough to examine its label, evidence and practical arrangements. Until then, a familiar hormone name is a starting point for clarification. This review offers no firsthand endorsement and no claim that regulatory or study information from a separate product authenticates what Stanford would prescribe to a particular patient.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Stanford Health Care — Menopause TreatmentsOfficial health-system clinical service, appointment or location page; exact product, personal access and full cost remain unconfirmed. · Checked 2026-09-29
- FDA — Hormone Replacement Therapies Can Help Women with Bothersome Menopausal SymptomsFederal primary therapy-category explanation. Active ingredients remain distinct; requested labeling changes do not establish removal of every warning or identify a clinic product. · Checked 2026-09-29
- DailyMed — PROMETRIUM progesterone capsule, Acertis Pharmaceuticals LLCExact identified oral product labeling, updated July 23, 2026; text only, no package-image inspection. Ingredient, formulation and WHI study details are not assigned to a health-system prescription. · Checked 2026-09-29
- Stanford Health Care — MenopauseOfficial health-system clinical service, appointment or location page; exact product, personal access and full cost remain unconfirmed. · Checked 2026-09-29